Venenum BioDesign, LLC的封面图片
Venenum BioDesign, LLC

Venenum BioDesign, LLC

生物技术研究

Hamilton，NJ 788 位关注者

DISCOVERY IS OUR MISSION

关注

关于我们

VENENUM Biodesign, a Genesis Drug Discovery and Development (GD3) Company, is focused on discovering and advancing innovative new medicines for significant unmet medical needs in key therapeutic areas, including; cancer, inflammation, infectious diseases, metabolic diseases, and women’s health. Our most advanced programs are targeting Clostridium difficile infection (CDI) and Type 2 Diabetes (T2D). Our business model allows us to focus on the creation of high value, innovative small molecule programs against well-validated targets, as well as new targets identified from our own research and to work with partners for clinical and commercial development to bring our products to patients. Our mission is to improve patients’ lives through the discovery of therapeutic compounds against our novel biological targets. Many of our targets involve novel protein-protein or protein-DNA interactions. Others are more conventional target classes e.g., GPCRs and enzymes. Our goal is to advance our discoveries to medicine through partnership with pharmaceutical companies. We utilize state-of-the-art assay development and ultra-high throughput screening (UHTS) against our proprietary 6 million ECLiPS compound collection in conjunction with protein engineering and structural biology, medicinal chemistry, and in vivo models.

网站
https://www.venenumbiodesign.com
所属行业
生物技术研究
规模
11-50 人
总部
Hamilton，NJ
类型
私人持股
创立
2009
领域
Drug Discovery、Medicinal Chemistry、High Throughput Screening、Compound Management、ADMET-PK和in vivo pharmacology

地点

Venenum BioDesign, LLC员工

查看全部员工

动态

  • Join us at the Society of Toxicology 64th Annual Meeting and #ToxExpo in Orlando, FL. Stop by our booth #1100 and speak with one of our GD3 experts to learn about our fully integrated CRO services and toxicology capabilities and how we can provide innovative support to advance the success of your program. Please click the following link to connect with the team https://lnkd.in/eRPXDeQz Mention this post when you visit us at booth 1100 to be entered into a raffle. #2025SOT

    • 该图片无替代文字

  • Immunoassays are essential tools in preclinical drug discovery and disease diagnostics. These sophisticated biochemical tests detect small molecules, proteins, nucleic acids, toxins, and other biological substances in a sample by utilizing antibodies that specifically bind to a target analyte or antigen. The resulting antibody-antigen complexes are then quantified by measuring the signal emitted from a detection label. Immunoassays have a wide range of applications, including quantifying test articles, diagnosing infectious diseases, evaluating immune responses to therapeutic candidates, and accurately measuring biomarkers and metabolites for drug development. At GD3, we offer both off-the-shelf and custom immunoassays tailored to meet your unique research requirements. Our scientists deliver quick turnaround times, assays with exceptional sensitivity and reproducibility, and a commitment to delivering high-quality results to advance your programs. Our wide range of services include: ?? ELISAs and ECL-based immunoassays ? Meso Scale Discovery (MSD) immunoassays ? Fluorescence resonance energy transfer (FRET) immunoassays ? Antibody purification and labeling ? I mmunogenicity assays ? Nuclease protection assays ? Ligand binding assays ? And More! Contact us to learn more about how GD3 can help you progress your research. Contact our experts today! https://lnkd.in/eRPXDeQz

    • 该图片无替代文字

  • Do you have an ocular therapeutic candidate for which you need safety assessment and toxicology data? The scientists at GD3 have extensive experience collecting and interpreting routine ocular readouts following test article administration through a variety of dose routes, including topical, intravitreal, subretinal and suprachoroidal. Using our state-of-the-art Heidelberg Spectralis HRA + OCT device, we can generate high-quality and consistent optical coherence tomography (OCT), fluorescein angiography (FA) and confocal scanning laser ophthalmoscopy (cSLO) data needed to continue advancing your therapeutic candidate through the drug development pipeline. The experts at GD3 are able to take these readouts a step further by quantitatively assessing visual function through the collection of electroretinograms (ERG) using our Celeris Diagnosys system, which enables our experts to execute the standard International Society for Clinical Electrophysiology of Vision (ISCEV) protocol that is routinely used in clinical studies. At GD3, we are invested in understanding the characteristics of your therapeutic candidate. We can offer guidance and expertise on standard OCT and ERG parameters required to assess ocular safety and toxicology, which can be modified to satisfy client and therapeutic candidate needs. Additional ocular safety assessment and toxicology readouts that are routinely performed and offered at GD3 include: ???? We offer additional ocular safety assessment and toxicology readouts that are routinely performed and offered at GD3 including: ? Indirect and slit lamp ocular examinations performed by a board-certified veterinary ophthalmologist ? Intraocular Pressure ? Pachymetry ? Modified Draize Scoring ? Depot imaging ? Data interpretation and summary of ocular readouts performed by a board-certified veterinary ophthalmologist ? Histopathological assessment with a board-certified pathologist ? Biomarker evaluation ? Gene expression analysis ? Bioanalysis for small molecules, peptides, proteins and nucleic-acid-based therapeutics ?? Connect with one of GD3's experts to learn more about how we can provide innovative support to advance the success of your program. https://lnkd.in/eRPXDeQz

    • Do you have an ocular therapeutic candidate for which you need safety assessment and toxicology data?

  • The first synthesis of acetylsalicylic acid was performed on the 10th of August 1897 by the German chemist Felix Hoffmann, who found that the addition of an acetyl group to salicylic acid reduced its irritant properties like nausea, tinnitus or gastric irritation. However, the appealing history of acetylsalicylic acid dates back to ancient times, when meadow sweet, willow and myrtle were used to relieve pain. Aspirin, the brand name of acetylsalicylic acid given by the German company Bayer, recognizes the fascinating herbal medicine from the past as "Spir" comes from the plant "Spiraea ulmaria" or meadow sweet, attributed as the botanical source of salicylic acid. Although the development of paracetamol and ibuprofen reduced the popularity of Aspirin, it is still the most commonly used drug in the world, is on the World Health Organization's List of Essential Medicines and has entered the Guinness Book of Records as the highest-selling painkiller. Speak with one of GD3's experts to learn more about our deep experience in medicinal chemistry and how we can advance your drug discovery and development program. Click here to reach a member of our team! https://lnkd.in/eRPXDeQz

    • 该图片无替代文字

  • August 05: American physician Seymour Lipsky was born on this day in 1924. He was the inventor of high-performance liquid chromatography (HPLC), which is a powerful analytical technique used to separate, identify, and quantify each component in a mixture. This invention in the 1960s revolutionized the field of analytical chemistry by providing a highly efficient method for the analysis of complex samples. In pharmaceutical analysis, HPLC is of paramount importance due to its accuracy, sensitivity, and versatility. It plays a critical role in drug development and quality control, ensuring that pharmaceutical products are safe, effective, and consistent. Speak with one of GD3’s experts to learn more about our deep experience in HPLC and other analytical techniques and how we can advance your drug discovery and development projects. Click here to reach out to our team! https://lnkd.in/eRPXDeQz

  • At GD3, we specialize in providing custom or off-the-shelf protein biomarker assays across various therapeutic areas, including immunology, ophthalmology, inflammation, infectious disease, oncology, CNS, and metabolic disease. Our expertise extends to method development, optimization, validation, and sample analysis, adhering to FDA GLP guidelines as necessary. We are equipped to handle both preclinical and clinical samples (GxP), ensuring rigorous standards and regulatory compliance throughout the drug development process. While the majority of commercially available biomarker assays are developed for human, mouse, rat, and non-human primate samples, we can develop custom assays for biomarkers for a variety of species. This capability supports researchers in translating proteomics insights into clinically meaningful applications, driving advancements in medicine and patient care. ???? We offer a wide range of services including: ? Meso Scale Discovery ECL-based immunoassays ? Colorimetric, luminescence and fluorescent-based ELISAs ? Protein purification and expression ? Protein-protein interactions and protein-DNA interactions ? Reporter bioassays and cell signaling assays ? Protein purity and aggregation analysis ? Western blots ? And More! ?? Connect with one of GD3's experts to learn more about how we can provide innovative support to advance the success of your program. https://lnkd.in/eRPXDeQz

  • ?? JSS, a Genesis Drug Discovery & Development (GD3) company, was deeply honored to receive recognition for more than 20 years of affiliation and active participation within the Association for the Advancement of Clinical Research in Colombia (AVANZAR). This award acknowledges JSS’s commitment, dedication, and excellence in the area of clinical research and contributions to the growth and development of #ClinicalResearch in Colombia and Latin America (LATAM) as a whole. ?? To speak with one of our experts and learn more about our capabilities and the benefits of conducting clinical trials in the LATAM region, click the following link https://lnkd.in/eRPXDeQz

    • 该图片无替代文字
  • 查看Venenum BioDesign, LLC的组织主页
    Venenum BioDesign, LLC

    788 位关注者

    Did you know? Everyday 6,000 people become newly infected with viral hepatitis, a leading cause of liver cancer. Tragically, this silent disease often goes unnoticed until later stages with many people unknowingly carrying and potentially transmitting the virus to others. #WorldHepatitisDay highlights the need for collaborative action to expand access to diagnosis and treatment. ?? GD3 offers a range of optimized and validated immune-mediated models suitable for the assessment of Hepatitis and other immune-mediated diseases. Our team of scientists is skilled in developing new or custom models. ???? Supporting capabilities include Hepatitis screening, genotyping and viral load detection; gene expression profiling, analysis of protein biomarkers, custom in vitro assay development, preclinical PK/PD, small and large molecule bioanalysis. ?? Extensive worldwide clinical trial experience ? >1,300 clinical trials overall ?? Extensive global network of sites with available performance metrics, academic & community-based ?? Your “One-Stop Shop” ? Study design ? Regulatory ? Project management ? Data management ? Clinical monitoring ? Medical monitoring ? Safety review / pharmacovigilance ? Biostatistical expertise ? Medical writing ?? DISC Gold Member: SDTM/ADaM expertise ?? Connect with one of GD3's experts to learn more about how we can provide innovative support to advance the success of your program. https://lnkd.in/ezTBzjzk

相似主页

查看职位